RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Luminopia: VR technology to treat lazy eye syndrome

Product
Developers: Luminopia
Date of the premiere of the system: June 2023
Branches: Pharmaceuticals, Medicine, Healthcare

2023: Digital Therapy Launch

On June 27, 2023, the American company Luminopia announced a virtual reality (VR) digital system for the treatment of amblyopia in children aged four to seven years.

Amblyopia, or lazy eye syndrome, is a variety of types of decline in vision quality, the causes of which are mainly functional disorders of the visual analyzer. Moreover, such deviations are usually not correctable with the help of glasses or contact lenses.

Digital therapy launched to treat 'lazy eye' disease

Luminopia technology is based on the use of a VR helmet, through which therapeutic content is shown to a small patient. These can be, for example, specially modified television shows and films, educational materials, etc. In total, Luminopia offers a choice of approximately 700 hours of therapeutic video. You must view the materials for one hour a day, six days a week. The course duration is 12 weeks. The system is suitable for patients with mild strabismus and anisometropic amblyopia. The technology, according to Luminopia itself, improves the quality of vision in 86% of children who have undergone therapy. It is also noted that 94% of young patients spoke in favor of the Luminopia method in comparison with traditional methods of therapy, such as the use of eye drops.

At the same time, Luminopia announced an expanded Series A funding round, during which $16 million was raised for further development. The program was led by U.S. Venture Partners (USVP) with the participation of Broadfin Advisors. In addition, the funds came from previous investors - ShangBay Capital and Vertical Group. At the same time, USVP general partner Casey Tansey will join the board of directors of Luminopia.[1]

Notes